GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » 5-Year Dividend Growth Rate

PuraPharm (HKSE:01498) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is PuraPharm 5-Year Dividend Growth Rate?

PuraPharm's Dividends per Share for the six months ended in Dec. 2024 was HK$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

PuraPharm's Dividend Payout Ratio for the six months ended in Dec. 2024 was 0.00. As of today, PuraPharm's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of PuraPharm's 5-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm's 5-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where PuraPharm's 5-Year Dividend Growth Rate falls into.


;
;

PuraPharm 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


PuraPharm  (HKSE:01498) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

PuraPharm's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2024 )/ EPS without NRI (Q: Dec. 2024 )
=0/ -0.052
=N/A

During the past 11 years, the highest Dividend Payout Ratio of PuraPharm was 2.71. The lowest was 0.66. And the median was 1.69.

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

During the past 11 years, the highest Dividend Yield of PuraPharm was 2.94%. The lowest was 0.00%. And the median was 1.75%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuraPharm 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of PuraPharm's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.
Executives
Chan Yu Ling, Abraham 2101 Beneficial owner
Man Yee Wai, Viola 2202 Interest of your spouse
Fullgold Development Limited 2101 Beneficial owner

PuraPharm Headlines

No Headlines